 Anne Lynch
Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 12 | 2022 | 111 | 5.400 |
Why?
| | Macular Degeneration | 12 | 2023 | 152 | 4.060 |
Why?
| | Complement Factor B | 7 | 2022 | 100 | 2.310 |
Why?
| | Geographic Atrophy | 7 | 2023 | 49 | 2.210 |
Why?
| | Neonatal Screening | 5 | 2022 | 151 | 1.750 |
Why?
| | Visual Acuity | 14 | 2023 | 272 | 1.730 |
Why?
| | Pre-Eclampsia | 7 | 2015 | 166 | 1.720 |
Why?
| | Wet Macular Degeneration | 4 | 2023 | 32 | 1.640 |
Why?
| | Birth Weight | 10 | 2022 | 439 | 1.620 |
Why?
| | Premature Birth | 5 | 2017 | 275 | 1.520 |
Why?
| | Cataract | 11 | 2023 | 184 | 1.490 |
Why?
| | Retinal Drusen | 2 | 2021 | 25 | 1.420 |
Why?
| | Complement Activation | 6 | 2022 | 337 | 1.390 |
Why?
| | Gestational Age | 14 | 2022 | 761 | 1.310 |
Why?
| | Phacoemulsification | 8 | 2023 | 106 | 1.230 |
Why?
| | Complement C3a | 2 | 2019 | 33 | 1.030 |
Why?
| | Infant, Premature | 6 | 2022 | 478 | 1.020 |
Why?
| | Diabetic Retinopathy | 5 | 2023 | 149 | 0.880 |
Why?
| | Cataract Extraction | 5 | 2023 | 75 | 0.850 |
Why?
| | Infant, Newborn | 14 | 2022 | 5038 | 0.830 |
Why?
| | Pregnancy | 24 | 2022 | 5499 | 0.790 |
Why?
| | Retrospective Studies | 34 | 2023 | 12521 | 0.770 |
Why?
| | Fetal Membranes, Premature Rupture | 3 | 2017 | 34 | 0.760 |
Why?
| | Weight Gain | 4 | 2019 | 453 | 0.740 |
Why?
| | Risk Factors | 19 | 2023 | 8614 | 0.720 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 92 | 0.710 |
Why?
| | Pregnancy Outcome | 7 | 2015 | 337 | 0.680 |
Why?
| | Infant, Low Birth Weight | 2 | 2017 | 124 | 0.670 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 33 | 0.650 |
Why?
| | Cohort Studies | 10 | 2020 | 4883 | 0.650 |
Why?
| | Registries | 5 | 2021 | 1764 | 0.630 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 44 | 0.630 |
Why?
| | Internet | 1 | 2023 | 591 | 0.620 |
Why?
| | Humans | 79 | 2023 | 114045 | 0.620 |
Why?
| | Female | 60 | 2023 | 59324 | 0.620 |
Why?
| | Algorithms | 6 | 2018 | 1469 | 0.610 |
Why?
| | Labor, Induced | 2 | 2017 | 32 | 0.580 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 176 | 0.570 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 35 | 0.560 |
Why?
| | Labor, Obstetric | 1 | 2017 | 52 | 0.550 |
Why?
| | Retinal Detachment | 3 | 2023 | 52 | 0.550 |
Why?
| | Colorado | 10 | 2023 | 4090 | 0.540 |
Why?
| | Blood Proteins | 2 | 2015 | 222 | 0.540 |
Why?
| | Pregnancy Trimester, First | 2 | 2015 | 125 | 0.500 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 286 | 0.480 |
Why?
| | Infant | 12 | 2022 | 7943 | 0.470 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 333 | 0.470 |
Why?
| | Placenta | 2 | 2018 | 628 | 0.460 |
Why?
| | Inflammation | 4 | 2023 | 2464 | 0.450 |
Why?
| | Infant, Very Low Birth Weight | 4 | 2019 | 66 | 0.450 |
Why?
| | Research Design | 1 | 2019 | 919 | 0.430 |
Why?
| | Intraoperative Complications | 4 | 2022 | 120 | 0.430 |
Why?
| | Tomography, Optical Coherence | 4 | 2023 | 130 | 0.420 |
Why?
| | Biomarkers | 8 | 2023 | 3397 | 0.420 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2012 | 138 | 0.420 |
Why?
| | Body Mass Index | 4 | 2014 | 1957 | 0.400 |
Why?
| | Aged | 20 | 2023 | 18969 | 0.390 |
Why?
| | Vitrectomy | 3 | 2021 | 57 | 0.390 |
Why?
| | Cesarean Section | 3 | 2011 | 169 | 0.390 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 0.380 |
Why?
| | Odds Ratio | 5 | 2019 | 951 | 0.380 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 57 | 0.370 |
Why?
| | Retinal Diseases | 2 | 2023 | 76 | 0.370 |
Why?
| | Male | 35 | 2023 | 55396 | 0.370 |
Why?
| | Pregnancy Complications | 3 | 2010 | 430 | 0.370 |
Why?
| | Myopia | 2 | 2022 | 36 | 0.370 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2012 | 285 | 0.360 |
Why?
| | Logistic Models | 8 | 2019 | 1829 | 0.360 |
Why?
| | Complement Activating Enzymes | 1 | 2010 | 3 | 0.340 |
Why?
| | Pregnant Women | 1 | 2011 | 129 | 0.330 |
Why?
| | Aged, 80 and over | 11 | 2023 | 6306 | 0.330 |
Why?
| | Influenza Vaccines | 2 | 2012 | 497 | 0.330 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 68 | 0.330 |
Why?
| | Intraocular Pressure | 4 | 2018 | 275 | 0.330 |
Why?
| | Obesity | 3 | 2014 | 2505 | 0.320 |
Why?
| | Prospective Studies | 13 | 2023 | 6195 | 0.320 |
Why?
| | Influenza, Human | 2 | 2012 | 543 | 0.310 |
Why?
| | Immunologic Factors | 2 | 2022 | 217 | 0.310 |
Why?
| | Adult | 23 | 2020 | 30375 | 0.310 |
Why?
| | Complement Pathway, Alternative | 2 | 2013 | 113 | 0.300 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 350 | 0.290 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1690 | 0.290 |
Why?
| | Antibodies, Antiphospholipid | 3 | 1999 | 21 | 0.290 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 787 | 0.290 |
Why?
| | Antigens, CD | 1 | 2010 | 440 | 0.280 |
Why?
| | Lenses, Intraocular | 3 | 2022 | 42 | 0.280 |
Why?
| | Follow-Up Studies | 9 | 2021 | 4392 | 0.280 |
Why?
| | Case-Control Studies | 7 | 2022 | 3003 | 0.270 |
Why?
| | Refraction, Ocular | 3 | 2022 | 30 | 0.270 |
Why?
| | Fluorescein Angiography | 3 | 2023 | 104 | 0.260 |
Why?
| | Incidence | 4 | 2022 | 2314 | 0.260 |
Why?
| | Glaucoma | 2 | 2018 | 201 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2011 | 1168 | 0.240 |
Why?
| | Postoperative Complications | 5 | 2023 | 2122 | 0.240 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 898 | 0.240 |
Why?
| | Membrane Proteins | 1 | 2010 | 1016 | 0.220 |
Why?
| | Vitreous Body | 2 | 2022 | 101 | 0.210 |
Why?
| | Methylprednisolone | 1 | 2023 | 80 | 0.210 |
Why?
| | Optic Neuritis | 1 | 2023 | 37 | 0.210 |
Why?
| | Vaccination | 1 | 2011 | 1202 | 0.210 |
Why?
| | Vision, Low | 1 | 2022 | 14 | 0.210 |
Why?
| | Proteomics | 2 | 2020 | 815 | 0.200 |
Why?
| | Photorefractive Keratectomy | 1 | 2022 | 13 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 213 | 0.200 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2022 | 16 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1422 | 0.200 |
Why?
| | Retinal Perforations | 1 | 2022 | 12 | 0.200 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Quality of Life | 5 | 2023 | 2343 | 0.190 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 92 | 0.190 |
Why?
| | Capsule Opacification | 1 | 2021 | 20 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 21 | 0.190 |
Why?
| | Complement System Proteins | 2 | 2022 | 281 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.180 |
Why?
| | Dementia | 1 | 2023 | 186 | 0.180 |
Why?
| | Risk Assessment | 3 | 2019 | 2958 | 0.180 |
Why?
| | Corneal Transplantation | 1 | 2020 | 10 | 0.180 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.180 |
Why?
| | Trabeculectomy | 2 | 2018 | 65 | 0.180 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.180 |
Why?
| | Abortion, Spontaneous | 2 | 1999 | 89 | 0.180 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 4595 | 0.180 |
Why?
| | United States | 8 | 2020 | 12137 | 0.180 |
Why?
| | Optics and Photonics | 1 | 2020 | 41 | 0.180 |
Why?
| | Strabismus | 1 | 2020 | 26 | 0.170 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 38 | 0.170 |
Why?
| | Laser Therapy | 1 | 2021 | 99 | 0.170 |
Why?
| | Middle Aged | 15 | 2023 | 26605 | 0.170 |
Why?
| | Hepatitis C | 1 | 2022 | 218 | 0.170 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 20 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.170 |
Why?
| | Macula Lutea | 1 | 2019 | 15 | 0.170 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 55 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2020 | 169 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2087 | 0.160 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.160 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 307 | 0.160 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 116 | 0.160 |
Why?
| | Disease Progression | 3 | 2022 | 2371 | 0.160 |
Why?
| | Pilocarpine | 1 | 2018 | 7 | 0.160 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1999 | 64 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.150 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 66 | 0.150 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.150 |
Why?
| | Metformin | 1 | 2021 | 274 | 0.150 |
Why?
| | Ocular Hypertension | 1 | 2018 | 61 | 0.150 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 445 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 77 | 0.140 |
Why?
| | Glycoproteins | 1 | 1999 | 304 | 0.140 |
Why?
| | Young Adult | 8 | 2019 | 10444 | 0.140 |
Why?
| | Laser Coagulation | 1 | 2017 | 53 | 0.140 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.140 |
Why?
| | Parity | 1 | 2017 | 97 | 0.140 |
Why?
| | Automobile Driving | 1 | 2018 | 129 | 0.140 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 94 | 0.130 |
Why?
| | Fetus | 2 | 2018 | 698 | 0.130 |
Why?
| | Time Factors | 4 | 2021 | 6077 | 0.130 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 15 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 573 | 0.130 |
Why?
| | Risk | 1 | 2018 | 810 | 0.120 |
Why?
| | Time-to-Pregnancy | 1 | 2015 | 3 | 0.120 |
Why?
| | Phenotype | 2 | 2022 | 2784 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 176 | 0.120 |
Why?
| | Mothers | 2 | 2018 | 650 | 0.120 |
Why?
| | Self Report | 1 | 2018 | 695 | 0.120 |
Why?
| | Proteins | 1 | 2020 | 906 | 0.120 |
Why?
| | Obstetric Labor, Premature | 1 | 2013 | 33 | 0.110 |
Why?
| | Sulfonamides | 1 | 2016 | 444 | 0.110 |
Why?
| | Cervical Ripening | 1 | 2013 | 8 | 0.110 |
Why?
| | Cervix Uteri | 1 | 2013 | 44 | 0.100 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 34 | 0.100 |
Why?
| | Pulmonary Fibrosis | 2 | 2008 | 321 | 0.100 |
Why?
| | Models, Statistical | 1 | 2016 | 595 | 0.100 |
Why?
| | Aspirin | 1 | 2015 | 324 | 0.100 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 4402 | 0.100 |
Why?
| | Fetal Blood | 1 | 2013 | 268 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2537 | 0.100 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 75 | 0.090 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 28 | 0.090 |
Why?
| | Autoantibodies | 1 | 1999 | 1347 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2015 | 395 | 0.090 |
Why?
| | Hypertension | 1 | 1999 | 1052 | 0.090 |
Why?
| | Adiposity | 1 | 2014 | 458 | 0.090 |
Why?
| | Endoglin | 1 | 2010 | 20 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2023 | 9049 | 0.090 |
Why?
| | Child | 4 | 2022 | 18401 | 0.080 |
Why?
| | Cesarean Section, Repeat | 1 | 2009 | 9 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 496 | 0.080 |
Why?
| | Postoperative Period | 2 | 2020 | 288 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2009 | 39 | 0.080 |
Why?
| | Models, Biological | 1 | 2016 | 1611 | 0.080 |
Why?
| | Placental Insufficiency | 1 | 2010 | 102 | 0.080 |
Why?
| | Academic Medical Centers | 2 | 2022 | 405 | 0.080 |
Why?
| | Health Status Disparities | 1 | 2011 | 200 | 0.080 |
Why?
| | Seasons | 1 | 2011 | 440 | 0.080 |
Why?
| | Heart Rate | 1 | 2012 | 710 | 0.080 |
Why?
| | Pregnancy Trimester, Third | 1 | 2008 | 79 | 0.080 |
Why?
| | Tonometry, Ocular | 2 | 2018 | 83 | 0.080 |
Why?
| | Elective Surgical Procedures | 1 | 2009 | 150 | 0.070 |
Why?
| | ROC Curve | 2 | 2019 | 441 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3254 | 0.070 |
Why?
| | Patient Compliance | 1 | 2011 | 524 | 0.070 |
Why?
| | Resuscitation | 1 | 2009 | 221 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2008 | 2272 | 0.070 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1011 | 0.070 |
Why?
| | Glyburide | 1 | 2006 | 35 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1791 | 0.070 |
Why?
| | Blood Pressure | 1 | 2012 | 1531 | 0.060 |
Why?
| | Fetal Growth Retardation | 2 | 2012 | 470 | 0.060 |
Why?
| | Ultrasonography, Doppler | 1 | 2005 | 104 | 0.060 |
Why?
| | Urban Health | 1 | 2004 | 73 | 0.060 |
Why?
| | Length of Stay | 1 | 2009 | 957 | 0.060 |
Why?
| | Papanicolaou Test | 1 | 2004 | 39 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2004 | 50 | 0.060 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2004 | 17 | 0.060 |
Why?
| | Uterus | 1 | 2005 | 191 | 0.060 |
Why?
| | Double-Blind Method | 4 | 2015 | 1656 | 0.060 |
Why?
| | Ovarian Follicle | 1 | 2004 | 61 | 0.060 |
Why?
| | Hospitals, County | 1 | 2023 | 10 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1381 | 0.050 |
Why?
| | Neuroprotection | 1 | 2023 | 30 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1310 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 128 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 204 | 0.050 |
Why?
| | Lasers, Excimer | 1 | 2022 | 21 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| | Diabetes, Gestational | 1 | 2006 | 281 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 141 | 0.050 |
Why?
| | Cornea | 1 | 2022 | 102 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 89 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 143 | 0.050 |
Why?
| | Vision Disorders | 1 | 2022 | 127 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 51 | 0.050 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 50 | 0.050 |
Why?
| | Hepacivirus | 1 | 2022 | 228 | 0.040 |
Why?
| | Adolescent | 5 | 2020 | 17800 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 8 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 15 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 45 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 51 | 0.040 |
Why?
| | Growth Charts | 1 | 2019 | 14 | 0.040 |
Why?
| | Canada | 1 | 2020 | 320 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 86 | 0.040 |
Why?
| | HIV | 1 | 2020 | 208 | 0.040 |
Why?
| | Child, Preschool | 3 | 2022 | 9114 | 0.040 |
Why?
| | beta 2-Glycoprotein I | 1 | 1999 | 3 | 0.040 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1999 | 5 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 37 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 675 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 183 | 0.040 |
Why?
| | Pulmonary Gas Exchange | 1 | 1999 | 117 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 273 | 0.040 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 68 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 1999 | 87 | 0.040 |
Why?
| | Family | 1 | 2022 | 589 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2018 | 9 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 14 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| | Confidence Intervals | 1 | 1999 | 302 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2022 | 632 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 1999 | 245 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 221 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 239 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2022 | 636 | 0.040 |
Why?
| | North America | 1 | 2018 | 255 | 0.040 |
Why?
| | Mental Health | 1 | 2022 | 559 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 723 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 503 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 286 | 0.030 |
Why?
| | Interferon-beta | 2 | 2008 | 79 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 1999 | 766 | 0.030 |
Why?
| | Plethysmography | 1 | 2014 | 103 | 0.030 |
Why?
| | Apgar Score | 1 | 1994 | 16 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1735 | 0.030 |
Why?
| | Mice | 1 | 2010 | 14843 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2008 | 522 | 0.030 |
Why?
| | Nitric Oxide | 1 | 1999 | 817 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 768 | 0.030 |
Why?
| | Treatment Failure | 2 | 2006 | 330 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 434 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2012 | 151 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2014 | 545 | 0.020 |
Why?
| | Body Composition | 1 | 2014 | 590 | 0.020 |
Why?
| | Prevalence | 1 | 1997 | 2247 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1080 | 0.020 |
Why?
| | Animals | 1 | 2010 | 31565 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2012 | 520 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 492 | 0.020 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 58 | 0.020 |
Why?
| | Rheology | 1 | 2005 | 86 | 0.020 |
Why?
| | Chicago | 1 | 2004 | 45 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1078 | 0.010 |
Why?
| | Survival Analysis | 1 | 2008 | 1206 | 0.010 |
Why?
| | Ethinyl Estradiol | 1 | 2004 | 17 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2004 | 31 | 0.010 |
Why?
| | Desogestrel | 1 | 2004 | 40 | 0.010 |
Why?
| | Ultrasonography, Prenatal | 1 | 2005 | 237 | 0.010 |
Why?
| | Menstrual Cycle | 1 | 2004 | 108 | 0.010 |
Why?
| | Women's Health | 1 | 2004 | 270 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 714 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 213 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 945 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1999 | 637 | 0.010 |
Why?
| | Oxygen | 1 | 1999 | 851 | 0.010 |
Why?
| | Hypoxia | 1 | 1999 | 956 | 0.010 |
Why?
|
|
Lynch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|